Figure 3From: Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritisDose-dependent arrest of disease activity by treatment withinterleukin (IL)-4 and IL-4/prednisolone (Pred). The enhanced disease activitybetween days 28 and 35 of each individual mouse is expressed as change in(Î) disease activity. For treatment protocol, see Fig. 2. P < 0.05, versus vehicle, by Mann-Whitney Utest.Back to article page